argenx SE (NASDAQ:ARGX) Shares Bought by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc lifted its position in shares of argenx SE (NASDAQ:ARGX) by 11.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,316 shares of the company’s stock after purchasing an additional 138 shares during the quarter. Marks Group Wealth Management Inc’s holdings in argenx were worth $809,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Advisors Preferred LLC purchased a new stake in argenx during the fourth quarter worth $73,000. Cromwell Holdings LLC boosted its stake in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares in the last quarter. GAMMA Investing LLC grew its position in shares of argenx by 44.8% during the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company’s stock valued at $155,000 after acquiring an additional 78 shares during the period. Blue Trust Inc. increased its stake in shares of argenx by 413.9% in the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares in the last quarter. Finally, Keudell Morrison Wealth Management acquired a new position in argenx in the 3rd quarter worth about $207,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Stock Up 2.1 %

Shares of NASDAQ:ARGX opened at $649.09 on Thursday. argenx SE has a 52-week low of $349.86 and a 52-week high of $678.21. The stock has a market cap of $39.44 billion, a P/E ratio of -737.60 and a beta of 0.58. The business has a fifty day moving average of $638.76 and a two-hundred day moving average of $580.34.

Wall Street Analyst Weigh In

Several analysts have commented on ARGX shares. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and raised their price objective for the company from $439.00 to $715.00 in a report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on shares of argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. Citigroup upped their price objective on shares of argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Evercore ISI lifted their target price on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Finally, Guggenheim boosted their target price on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.